Helen Torley

Insider Reports History

Entity
Individual
Location
C/O Onyx Pharmaceuticals, Inc., 249 East Grand Ave., South San Francisco, CA
Signature
/s/ James R. Oehler, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Helen Torley:

Stock Role Class Num Shares Value Price $ Report Date Ownership
HALOZYME THERAPEUTICS, INC. PRESIDENT AND CEO, Director Common Stock 667K $35.5M $53.26 Nov 29, 2024 Direct
HALOZYME THERAPEUTICS, INC. PRESIDENT AND CEO, Director Restricted Stock Units 89.7K $3.24M $36.10 Feb 23, 2024 Direct
HALOZYME THERAPEUTICS, INC. PRESIDENT AND CEO, Director Option to Purchase Common Stock 93K $1.29M $13.87 Feb 23, 2024 Direct
QUEST DIAGNOSTICS INC Director Common Stock 6.26K $769K $122.86 May 25, 2021 Direct
HALOZYME THERAPEUTICS, INC. PRESIDENT AND CEO, Director Option to Purchase Common Stock 0 $0 $13.87 Oct 9, 2024 Direct

Insider Reports Filed by Helen Torley

Symbol Company Period Transactions Value $ Form Type Date Filed Role
HALO HALOZYME THERAPEUTICS, INC. Nov 29, 2024 1 $0 4 Dec 3, 2024 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Oct 8, 2024 9 -$1.07M 4 Oct 9, 2024 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Sep 24, 2024 9 -$1.71M 4 Sep 26, 2024 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Sep 10, 2024 9 -$1.77M 4 Sep 12, 2024 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Aug 13, 2024 11 -$1.71M 4 Aug 15, 2024 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Feb 23, 2024 2 $0 4 Feb 27, 2024 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Feb 16, 2024 6 -$735K 4 Feb 20, 2024 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Feb 15, 2024 5 -$885K 4 Feb 16, 2024 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Feb 10, 2024 3 -$601K 4 Feb 13, 2024 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Aug 29, 2023 9 -$1.28M 4 Aug 31, 2023 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Aug 15, 2023 9 -$1.3M 4 Aug 17, 2023 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Jul 25, 2023 9 -$1.29M 4 Jul 27, 2023 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Mar 7, 2023 9 -$1.31M 4 Mar 9, 2023 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Mar 1, 2023 1 $0 4 Mar 1, 2023 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Feb 16, 2023 5 -$545K 4 Feb 21, 2023 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Feb 15, 2023 3 -$339K 4 Feb 17, 2023 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Feb 10, 2023 6 -$1.65M 4 Feb 14, 2023 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Feb 7, 2023 9 -$1.53M 4 Feb 9, 2023 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Jan 17, 2023 10 -$1.54M 4 Jan 19, 2023 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Dec 13, 2022 11 -$1.74M 4 Dec 15, 2022 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Nov 15, 2022 10 -$1.6M 4 Nov 17, 2022 PRESIDENT AND CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Feb 15, 2022 5 -$237K 4 Feb 17, 2022 President and CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Feb 10, 2022 9 -$1.68M 4 Feb 14, 2022 President and CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Nov 8, 2021 4 -$1.99M 4 Nov 8, 2021 President and CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Oct 4, 2021 4 -$2M 4 Oct 4, 2021 President and CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Sep 7, 2021 4 -$2.12M 4 Sep 7, 2021 President and CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Aug 10, 2021 8 -$2.06M 4 Aug 10, 2021 President and CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Jul 6, 2021 3 -$2.3M 4 Jul 6, 2021 President and CEO, Director
HALO HALOZYME THERAPEUTICS, INC. Jun 7, 2021 3 -$1.98M 4 Jun 7, 2021 President and CEO, Director
DGX QUEST DIAGNOSTICS INC May 25, 2021 1 $0 4 May 25, 2021 Director
HALO HALOZYME THERAPEUTICS, INC. May 11, 2021 6 -$2.15M 4 May 11, 2021 President and CEO, Director